Pfizer, the big pharma giant has started investing in biosimilars as you already know.Last year, we have informed you about the initiation of rituximab biosimilar trial and they are also carrying out a trial for a biosimilar version of trastuzumab.
This time, according to clinicaltrials.gov, we can see that, Pfizer has started recruiting patients for adalimuma biosimilar phase I trial. The reference medicine is Humira, which is used in several indications including rheumatoid arthritis.
This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 and the licensed adalimumab products.